Aprea Therapeutics (NASDAQ:APRE) Announces Earnings Results, Beats Estimates By $0.01 EPS

Aprea Therapeutics (NASDAQ:APRE) issued its quarterly earnings results on Wednesday. The company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.01, FiscalAI reports. The firm had revenue of $0.28 million for the quarter, compared to analysts’ expectations of $0.00 million. Aprea Therapeutics had a negative return on equity of 97.54% and a negative net margin of 4,405.59%.

Aprea Therapeutics Price Performance

NASDAQ:APRE opened at $0.94 on Friday. Aprea Therapeutics has a fifty-two week low of $0.55 and a fifty-two week high of $2.22. The stock’s 50-day moving average is $0.82 and its two-hundred day moving average is $0.91. The stock has a market cap of $11.65 million, a PE ratio of -0.61 and a beta of 1.48.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on APRE. Weiss Ratings reissued a “sell (e+)” rating on shares of Aprea Therapeutics in a research note on Monday, April 20th. Wedbush dropped their price target on Aprea Therapeutics from $7.00 to $6.00 and set an “outperform” rating on the stock in a research note on Thursday. Zacks Research raised Aprea Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, February 16th. HC Wainwright dropped their price target on Aprea Therapeutics from $4.00 to $1.20 and set a “buy” rating on the stock in a research note on Tuesday, March 31st. Finally, Oppenheimer began coverage on Aprea Therapeutics in a research note on Thursday, May 7th. They issued an “outperform” rating and a $5.00 price target on the stock. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $4.07.

Hedge Funds Weigh In On Aprea Therapeutics

An institutional investor recently bought a new position in Aprea Therapeutics stock. Jane Street Group LLC purchased a new stake in Aprea Therapeutics, Inc. (NASDAQ:APRE) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 46,621 shares of the company’s stock, valued at approximately $40,000. Jane Street Group LLC owned approximately 0.67% of Aprea Therapeutics as of its most recent filing with the SEC. Institutional investors own 34.19% of the company’s stock.

Aprea Therapeutics Company Profile

Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.